Trial and error — a phrase Kelly Summers lives by.
“The idea behind these drugs is that they would target those metals in areas of the brain,” said the University of Saskatchewan chemistry PhD student.
“Where they have accumulated and try to restore the balance within the brain.”
That metal is copper.
She says in Alzheimer’s patients the levels of copper hit toxic levels forming plaques in the brain.
“It’s really striking the difference the mass or size of the brain of an Alzheimer’s patient is than a normal, healthy human brain,” she said.
U of S Geological Sciences professor and supervisor of the team, Graham George (DSc'19), says Kelly’s work “is paving the way for understanding how the drugs based molecules function and interact with copper.”
Currently, testing is limited to lab mice.
“This might help Alzheimer’s victims by removing some of their toxicity of the amyloid plaques,” he said.
Read more at https://globalnews.ca/news.